These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15283304)

  • 1. Impact of truncated area under the curve on failed bioequivalence studies: a computer simulation analysis.
    Mahmood I
    Drug Metabol Drug Interact; 2004; 20(1-2):77-83. PubMed ID: 15283304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Truncating AUC at 12, 24 and 48 hr When Evaluating the Bioequivalence of Drugs with a Long Half-Life.
    Moreno I; Ochoa D; Román M; Cabaleiro T; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):53-7. PubMed ID: 26086613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial-area method in bioequivalence assessment: naproxen.
    Niazi SK; Alam SM; Ahmad SI
    Biopharm Drug Dispos; 1997 Mar; 18(2):103-16. PubMed ID: 9099447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives.
    Endrenyi L; Tothfalusi L
    Int J Clin Pharmacol Ther; 1997 Apr; 35(4):142-50. PubMed ID: 9112134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
    Mahmood I; Mahayni H
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):275-81. PubMed ID: 10395118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Truncated AUCs in the assessment of the bioequivalence of topiramate, a long half-life drug.
    Almeida S; Spínola AC; Filipe A; Trabelsi F; Farré A
    Arzneimittelforschung; 2007; 57(5):249-53. PubMed ID: 17598694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine.
    Erkent U; Koytchev R
    Arzneimittelforschung; 2008; 58(5):255-8. PubMed ID: 18589560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions.
    Almeida S; Filipe A; Neves R; Pinho C; Pedroso P; Castillo A; Trabelsi F
    Arzneimittelforschung; 2011; 61(1):32-9. PubMed ID: 21355444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of long half-life drugs--informative sampling determination--using truncated area in parallel-designed studies for slow sustained-release formulations.
    El-Tahtawy A; Harrison F; Zirkelbach JF; Jackson AJ
    J Pharm Sci; 2012 Nov; 101(11):4337-46. PubMed ID: 22927120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Truncated Area on Point Estimate and Intra-Subject Variability in Bioequivalence of Dutasteride with Long Half-Life.
    Prasaja B; Harahap Y; Lusthom W; Yumi L; Sofiana A; Sandra M; Safira F; Chilmi U
    Drug Res (Stuttg); 2018 Apr; 68(4):238-240. PubMed ID: 29156456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of length of sampling schedule and washout interval on magnitude of drug carryover from period 1 to period 2 in two-period, two-treatment bioequivalence studies and its attendant effects on determination of bioequivalence.
    Dhariwal K; Jackson A
    Biopharm Drug Dispos; 2003 Jul; 24(5):219-28. PubMed ID: 12784322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve. A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions.
    Almeida S; Filipe A; Neves R; Desjardins I; Shink E; Castillo A
    Arzneimittelforschung; 2010; 60(3):116-23. PubMed ID: 20422942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF).
    Martinez MN; Jackson AJ
    Pharm Res; 1991 Apr; 8(4):512-7. PubMed ID: 1871049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
    Sathe P; Venitz J; Lesko L
    Pharm Res; 1999 Jun; 16(6):939-43. PubMed ID: 10397617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental, extrapolated and truncated areas under the concentration-time curve in bioequivalence trials.
    Marzo A; Monti NC; Vuksic D
    Eur J Clin Pharmacol; 1999 Nov; 55(9):627-31. PubMed ID: 10638390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a limited sampling method used to determine the bioequivalence of highly variable drugs with long half-lives.
    Jackson AJ
    Biopharm Drug Dispos; 2001 Jul; 22(5):179-90. PubMed ID: 11745920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
    Walker SE; Friesen MH
    J Pharm Pharm Sci; 1999; 2(1):15-22. PubMed ID: 10951658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.
    Gaudreault J; Potvin D; Lavigne J; Lalonde RL
    Pharm Res; 1998 Oct; 15(10):1621-9. PubMed ID: 9794507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Simulation of bioequivalence study on the base of dissolution curves].
    Grezál G; Vereczkey L
    Acta Pharm Hung; 2012; 82(2):55-9. PubMed ID: 22870777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations.
    Joukhadar C; Schenk B; Kaehler ST; Kollenz CJ; Bauer P; Müller M; Eichler HG
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):631-6. PubMed ID: 14564429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.